A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

(2012) Sebastian Böttcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Normal levels of peripheral CD19+CD5+ CLL-like cells: Toward a defined threshold for CLL follow-up-A GEIL-GOELAMS study

(2011) Françoise Durrieu et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

(2011) Eric van den Neste et al.   LEUKEMIA & LYMPHOMA

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

(2009) S Böttcher et al.   LEUKEMIA

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD